Allogeneic hematopoietic cell transplantation for myelofibrosis in the era of JAK inhibitors
V Gupta, P Hari, R Hoffman - … Journal of the American Society of …, 2012 - ashpublications.org
The discovery of JAK2617F mutation paved the way for the development of small molecule
inhibitors of JAK1/2 resulting in first approved JAK1/2 inhibitor, ruxolitinib, for the treatment of …
inhibitors of JAK1/2 resulting in first approved JAK1/2 inhibitor, ruxolitinib, for the treatment of …
Genetic analysis of patients with leukemic transformation of myeloproliferative neoplasms shows recurrent SRSF2 mutations that are associated with adverse …
SJ Zhang, R Rampal, T Manshouri… - Blood, The Journal …, 2012 - ashpublications.org
Leukemic transformation (LT) of myeloproliferative neoplasms (MPNs) is associated with a
poor prognosis and resistance to therapy. Although previous candidate genetic studies have …
poor prognosis and resistance to therapy. Although previous candidate genetic studies have …
Phase 2 study of the JAK kinase inhibitor ruxolitinib in patients with refractory leukemias, including postmyeloproliferative neoplasm acute myeloid leukemia
A Eghtedar, S Verstovsek, Z Estrov… - Blood, The Journal …, 2012 - ashpublications.org
We conducted a phase 2 study of ruxolitinib in patients with relapsed/refractory leukemias.
Patients with acceptable performance status (0-2), adequate organ function, and no active …
Patients with acceptable performance status (0-2), adequate organ function, and no active …
IDH mutations in primary myelofibrosis predict leukemic transformation and shortened survival: clinical evidence for leukemogenic collaboration with JAK2V617F
A Tefferi, T Jimma, NH Sulai, TL Lasho, CM Finke… - Leukemia, 2012 - nature.com
Isocitrate dehydrogenase (IDH) mutations are frequent in blast-phase myeloproliferative
neoplasms and might therefore contribute to leukemic transformation. We examined this …
neoplasms and might therefore contribute to leukemic transformation. We examined this …
Molecular alterations of isocitrate dehydrogenase 1 and 2 (IDH1 and IDH2) metabolic genes and additional genetic mutations in newly diagnosed acute myeloid …
S Chotirat, W Thongnoppakhun… - Journal of hematology & …, 2012 - Springer
Background Isocitrate dehydrogenase 1 and 2 (IDH1 and IDH2) metabolic genes encode
cytosolic and mitochondrial enzymes that catalyze the conversion of isocitrate to α …
cytosolic and mitochondrial enzymes that catalyze the conversion of isocitrate to α …
Guideline for the diagnosis and management of myelofibrosis
JT Reilly, MF McMullin, PA Beer, N Butt… - British journal of …, 2012 - Wiley Online Library
The guideline group regarding the diagnosis and management of myelofibrosis was
selected to be representative of UK‐based medical experts, together with a contribution from …
selected to be representative of UK‐based medical experts, together with a contribution from …
Transformation of a chronic myeloproliferative neoplasm to acute myelogenous leukemia: does anything work?
MN Kundranda, R Tibes, RA Mesa - Current hematologic malignancy …, 2012 - Springer
The BCR/ABL-negative myeloproliferative neoplasms (MPNs) of essential thrombocythemia,
polycythemia vera, and primary myelofibrosis, over the natural course of their disease, have …
polycythemia vera, and primary myelofibrosis, over the natural course of their disease, have …
The outcome of allo-HSCT for 92 patients with myelofibrosis in the Nordic countries
J Abelsson, M Merup, G Birgegård… - Bone marrow …, 2012 - nature.com
Between 1982 and 2009 a total of 92 patients with myelofibrosis (MF) in chronic phase
underwent allo-SCT in nine Nordic transplant centers. Myeloablative conditioning (MAC) …
underwent allo-SCT in nine Nordic transplant centers. Myeloablative conditioning (MAC) …
Proposed criteria for response assessment in patients treated in clinical trials for myeloproliferative neoplasms in blast phase (MPN-BP): formal recommendations from …
J Mascarenhas, ML Heaney, V Najfeld, E Hexner… - Leukemia research, 2012 - Elsevier
Leukemic transformation (LT) of a myeloproliferative neoplasm (MPN) is associated with a
dismal prognosis and no medical therapies have shown a survival improvement in patients …
dismal prognosis and no medical therapies have shown a survival improvement in patients …
Allogeneic stem cell transplantation for myeloproliferative neoplasm in blast phase
C Cherington, JL Slack, J Leis, RH Adams… - Leukemia research, 2012 - Elsevier
The prognosis for patients with Philadelphia-negative myeloproliferative neoplasms (MPN)
who evolve into acute myeloid leukemia (AML) or blast phase (MPN-BP) is extremely poor …
who evolve into acute myeloid leukemia (AML) or blast phase (MPN-BP) is extremely poor …